Detail
| LncRNA Name | RP11-135L22.1 |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qRT-PCR, Western blot |
| Sample | ovarian cancer tissues, ovarian cancer cell lines (A2780, HEY, HO8910) |
| Expression Pattern | down-regulated |
| Function Description | RP11-135L22.1 was lowly expressed in ovarian cancer.RP11-135L22.1 expression was negatively correlated with the treating time and dose of cisplatin. Western blot showed that cisplatin induced autophagy in ovarian cancer cells in a time- and dose-dependent manner. Cisplatin combined with RP11-135L22.1 can reduce autophagy, increase the apoptosis and inhibit its activity of ovarian cancer cells to a certain extent. |
| Pubmed ID | 29509240 |
| Year | 2018 |
| Title | Cisplatin suppresses tumor proliferation by inhibiting autophagy in ovarian cancer via long non-coding RNA RP11-135L22.1. |
| External Links |
| Links for RP11-135L22.1 | GenBank HGNC lncrnadb Noncode |
| Links for ovarian cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.